Evogene Ltd. – NASDAQ:EVGN
Evogene Ltd. stock price today
$1.29
-0.35
-21.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Evogene Ltd. stock price monthly change
+159.84%
month
Evogene Ltd. stock price quarterly change
+159.84%
quarter
Evogene Ltd. stock price yearly change
+95.38%
year
Evogene Ltd. key metrics
Market Cap | 7.72M |
Enterprise value | 3.56M |
P/E | -0.89 |
EV/Sales | 2.68 |
EV/EBITDA | -0.13 |
Price/Sales | 17.71 |
Price/Book | 0.76 |
PEG ratio | -0.05 |
EPS | -0.45 |
Revenue | 9.18M |
EBITDA | -19.92M |
Income | -21.47M |
Revenue Q/Q | 553.66% |
Revenue Y/Y | 341.99% |
Profit margin | -2338.69% |
Oper. margin | -2402.04% |
Gross margin | 38.76% |
EBIT margin | -2402.04% |
EBITDA margin | -216.88% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEvogene Ltd. stock price history
Evogene Ltd. stock forecast
Evogene Ltd. financial statements
| Jun 2023 | 654K | -7.02M | -1073.85% |
|---|---|---|---|
| Sep 2023 | 3.76M | -3.98M | -105.76% |
| Dec 2023 | 578K | -6.60M | -1142.04% |
| Mar 2024 | 4.19M | -3.86M | -92.2% |
| Dec 2023 | 578K | -6.60M | -1142.04% |
|---|---|---|---|
| Mar 2024 | 4.19M | -3.86M | -92.2% |
| Sep 2025 | 14M | -506.22K | -3.62% |
| Dec 2025 | 8M | -3.54M | -44.3% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-17 | -0.2 | -0.16 |
|---|---|---|
| 2023-03-09 | -0.0245 | -0.07 |
| Jun 2023 | 53340000 | 22.23M | 41.68% |
|---|---|---|---|
| Sep 2023 | 57746000 | 21.88M | 37.9% |
| Dec 2023 | 51101000 | 17.99M | 35.2% |
| Mar 2024 | 46780000 | 21.39M | 45.74% |
| Jun 2023 | -5.09M | -7.9M | 10.44M |
|---|---|---|---|
| Sep 2023 | -4.31M | 3.64M | 7.79M |
| Dec 2023 | -5.66M | -551.35K | -147K |
| Mar 2024 | -4.11M | -4.36M | -367K |
Evogene Ltd. alternative data
| Aug 2023 | 137 |
|---|---|
| Sep 2023 | 137 |
| Oct 2023 | 137 |
| Nov 2023 | 137 |
| Dec 2023 | 137 |
| Jan 2024 | 137 |
| Feb 2024 | 137 |
| Mar 2024 | 137 |
| Apr 2024 | 137 |
| May 2024 | 142 |
| Jun 2024 | 142 |
| Jul 2024 | 142 |
Evogene Ltd. other data
0.93%
-1.71%
of EVGN is owned by hedge funds
384.29K
-703.77K
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 23 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 15 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 18 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Ofer Haviv CPA (1966) Chief Executive Officer, Pres & Chairman of Lavie Bio Ltd. | $498,000 |
Ms. Dorit Kreiner (1972) Chief Financial Officer | $258,000 |
Mr. Mark Kapel (1977) Executive Vice President of Technology | $251,000 |
Dr. Arnon Heyman (1978) Chief Executive Officer of Canonic Ltd | $248,000 |
Evogene Subsidiary Casterra Ag: Castor Seeds Benefiting From Changes In EU Laws
Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck
Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus
Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)
Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market
Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets
Evogene's Canonic Positioned To Enter Israeli Medical Cannabis Market
-
What's the price of Evogene Ltd. stock today?
One share of Evogene Ltd. stock can currently be purchased for approximately $1.29.
-
When is Evogene Ltd.'s next earnings date?
Unfortunately, Evogene Ltd.'s (EVGN) next earnings date is currently unknown.
-
Does Evogene Ltd. pay dividends?
No, Evogene Ltd. does not pay dividends.
-
How much money does Evogene Ltd. make?
Evogene Ltd. has a market capitalization of 7.72M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 236.72% to 5.64M US dollars. Evogene Ltd. made a loss 23.88M US dollars in net income (profit) last year or -$0.07 on an earnings per share basis.
-
What is Evogene Ltd.'s stock symbol?
Evogene Ltd. is traded on the NASDAQ under the ticker symbol "EVGN".
-
What is Evogene Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Evogene Ltd.?
Shares of Evogene Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Evogene Ltd.'s key executives?
Evogene Ltd.'s management team includes the following people:
- Mr. Ofer Haviv CPA Chief Executive Officer, Pres & Chairman of Lavie Bio Ltd.(age: 59, pay: $498,000)
- Ms. Dorit Kreiner Chief Financial Officer(age: 53, pay: $258,000)
- Mr. Mark Kapel Executive Vice President of Technology(age: 48, pay: $251,000)
- Dr. Arnon Heyman Chief Executive Officer of Canonic Ltd(age: 47, pay: $248,000)
-
How many employees does Evogene Ltd. have?
As Jul 2024, Evogene Ltd. employs 142 workers, which is 4% more then previous quarter.
-
When Evogene Ltd. went public?
Evogene Ltd. is publicly traded company for more then 14 years since IPO on 15 Oct 2010.
-
What is Evogene Ltd.'s official website?
The official website for Evogene Ltd. is evogene.com.
-
How can i contact Evogene Ltd.?
Evogene Ltd. can be reached via phone at +972 8 931 1900.
Evogene Ltd. company profile:
Evogene Ltd.
evogene.comExchange:
NASDAQ
Full time employees:
142
Industry:
Biotechnology
Sector:
Healthcare
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
13 Gad Feinstein Street
Rehovot, 7414002
Rehovot, 7414002
CIK: 0001574565
ISIN: IL0011050551
CUSIP: M4119S104
